Three Years After Legalization, Canada Has Little Information About How It Changed Cannabis Use and Health Harms

In an editorial piece penned by Public Health Physician and Canadian Institutes of Health Research Fellow Daniel Myran for The Conversation, Dr. Myran explains the lack of timely and current data on recreational cannabis legalization before a mandated review of the health impacts.

He cites three main areas that limit the understanding of legalization’s health impact. First, almost all studies to date examining the impact of legalization on cannabis use and harms have only looked at changes during the first year following legalization. Second, many types of cannabis products, including commercially produced edibles such as THC-containing candies, desserts and drinks, only became available for sale in January 2020. Last, over half of the time since legalization has been during the pandemic. There is no easy way to separate the effects of the pandemic versus a maturing cannabis market on the recent increases in cannabis use.

To read the full story, click here: https://theconversation.com/3-years-after-legalization-we-have-shockingly-little-information-about-how-it-changed-cannabis-use-and-health-harms-169815

For more information on the International Academy on the Science and Impact of Cannabis, and to join, please visit www.IASIC1.org.

Visit the IASIC Library here (https://iasic1.org/library/). The IASIC Library is intended as a user-friendly reference of the published medical literature.

Like this article?

Share on Facebook
Share on Twitter
Share on Linkdin
Share on Pinterest

Leave a comment

Related Posts

Weed users nearly 25% more likely to need emergency care and hospitalization

The study, published Monday in the journal BMJ Open Respiratory Research, looked at national health records data for over 30,000 Ontario, Canada, residents between the ages of 12 and 65 over a six-year period. When compared with people who did not use marijuana, cannabis users were 22% more likely to visit an emergency department or be

Cannabis use is associated with increased risk for serious adverse health events

Although no significant association was observed between cannabis use and respiratory-related ER visits or hospitalisations, the risk of an equally important morbidity outcome, all-cause ER visit or hospitalisation, was significantly greater among cannabis users than among control individuals. Therefore, cannabis use is associated with increased risk for serious adverse health events and its recreational consumption

Cannabinoid Content and Label Accuracy of Hemp-Derived Topical Products Available Online and at National Retail Stores

Products containing cannabinoids such as cannabidiol (CBD) have proliferated since 2018, when the Agriculture Improvement Act removed hemp (ie, cannabis containing <0.3% Δ9-tetrahydrocannabinol [THC]) from the US controlled substances list. Topical cannabinoid products can be purchased nationwide at retail stores and over the internet, yet research on these products is scarce. The objective of this

Cannabis-Derived Oromucosal Spray Misses in MS Spasticity Trial

Topline results were announced from a phase 3 trial evaluating the efficacy and safety of nabiximols oromucosal spray (JZP378) on clinical measures of spasticity in adults with multiple sclerosis. Nabiximols oromucosal spray is an investigational complex botanical mixture formulated from extracts of the cannabis sativa plant. The investigational treatment contains the cannabinoids delta-9-tetrahydrocannabinol (THC) and

Should the UK legalize marijuana?

After Sadiq Khan’s visit to a California cannabis farm, discussions of legalising the herb here in the UK has been brought back into the spot light. But is Mr. Khan’s glowing review of the US marijuana industry all it’s cracked up to be? The Medical Minefield speak with Michelle Leopold, whose campaigning for safer drug

Scroll to Top